Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219822 | 0.89 | KDM4E (0.32) | KDM4EATRLMNAMAPK1 | |
| SCHEMBL31219573 | 0.87 | NNMT (0.31) | RET | |
| SCHEMBL28389771 | 0.80 | GRM5 (0.36) | KDM4ERETMAPK1ALKGAA | |
| SCHEMBL29402440 | 0.80 | GRM5 (0.36) | KDM4ERETMAPK1ALKGAA | |
| SCHEMBL15357877 | 0.79 | CYP46A1 (0.40) | KDM4ERETLMNAALKGAA | |
| SCHEMBL23051557 | 0.78 | GAA (0.42) | KDM4ELMNAGAA | |
| SCHEMBL29707038 | 0.78 | GAA (0.42) | KDM4ELMNAGAA | |
| SCHEMBL31219562 | 0.76 | — | — | |
| SCHEMBL15360290 | 0.76 | MAOB (0.42) | KDM4EMAPK1 | |
| SCHEMBL31219830 | 0.76 | KDM4E (0.41) | KDM4EATRLMNAMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |